Αρχική World News EMA Recommends Extension of Indications for Dostarlimab World News EMA Recommends Extension of Indications for Dostarlimab Από Ogkologos - 23 Ιανουαρίου, 2025 758 0 Facebook Twitter Google+ Pinterest WhatsApp Change concerns the first-line treatment of patients with endometrial cancer Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR When Natural Disasters Strike, This Program Helps Provide Relief To People... 3 Οκτωβρίου, 2019 African American Men More Likely to Die from Low-Grade Prostate Cancer 28 Ιανουαρίου, 2019 Neoadjuvant Histotype-Tailored Treatment with Trabectedin Not Inferior to Standard Chemotherapy with... 22 Ιανουαρίου, 2024 CAR22 Shows Durable Efficacy After a Single Infusion in Patients with... 25 Ιουλίου, 2024 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Granting a Marketing Authorisation for the Medicinal Product Nyvepria How Early Cancer Detection and Diagnosis Saved My Life Twice: A... For Esophageal Cancer, Immunotherapy Likely to Play Larger Role EMA Recommends Granting a Marketing Authorisation for Relacorilant